Management of bowel obstruction in advanced cancer

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Bowel obstruction is a common and distressing outcome in patients with abdominal or pelvic cancer. Patients may develop bowel obstruction at any time in their clinical history, with a prevalence ranging from 5.5% to 42% in those with ovarian cancer and from 10% to 28.4% in those with colorectal cancer. The causes of the obstruction may be benign postoperative adhesions, a focal malignant or benign deposit, or relapse or diffuse carcinomatosis. The symptoms, which are almost always present, are intestinal colic, continuous abdominal pain, nausea, and vomiting. Although surgery should be the primary treatment for malignant obstruction, it is now recognized that some patients with advanced disease or in generally poor condition are unfit for surgery and require alternative management to relieve distressing symptoms. A number of treatment options are now available for the patient with advanced cancer who develops intestinal obstruction. In this review, the indications for surgery are examined, the use of nasogastric tube and percutaneous gastrostomy evaluated, and the pharmacologic approach described.

Original languageEnglish
Pages (from-to)351-357
Number of pages7
JournalCurrent Opinion in Oncology
Volume6
Issue number4
Publication statusPublished - 1994

Fingerprint

Neoplasms
Pelvic Neoplasms
Focal Adhesions
Gastrostomy
Colic
Intestinal Obstruction
Ovarian Neoplasms
Nausea
Abdominal Pain
Vomiting
Colorectal Neoplasms
Carcinoma
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Cancer Research

Cite this

Management of bowel obstruction in advanced cancer. / Ripamonti, C.

In: Current Opinion in Oncology, Vol. 6, No. 4, 1994, p. 351-357.

Research output: Contribution to journalArticle

@article{9b80d7bdcf3e441ab7cb04ff8f1ff96f,
title = "Management of bowel obstruction in advanced cancer",
abstract = "Bowel obstruction is a common and distressing outcome in patients with abdominal or pelvic cancer. Patients may develop bowel obstruction at any time in their clinical history, with a prevalence ranging from 5.5{\%} to 42{\%} in those with ovarian cancer and from 10{\%} to 28.4{\%} in those with colorectal cancer. The causes of the obstruction may be benign postoperative adhesions, a focal malignant or benign deposit, or relapse or diffuse carcinomatosis. The symptoms, which are almost always present, are intestinal colic, continuous abdominal pain, nausea, and vomiting. Although surgery should be the primary treatment for malignant obstruction, it is now recognized that some patients with advanced disease or in generally poor condition are unfit for surgery and require alternative management to relieve distressing symptoms. A number of treatment options are now available for the patient with advanced cancer who develops intestinal obstruction. In this review, the indications for surgery are examined, the use of nasogastric tube and percutaneous gastrostomy evaluated, and the pharmacologic approach described.",
author = "C. Ripamonti",
year = "1994",
language = "English",
volume = "6",
pages = "351--357",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Management of bowel obstruction in advanced cancer

AU - Ripamonti, C.

PY - 1994

Y1 - 1994

N2 - Bowel obstruction is a common and distressing outcome in patients with abdominal or pelvic cancer. Patients may develop bowel obstruction at any time in their clinical history, with a prevalence ranging from 5.5% to 42% in those with ovarian cancer and from 10% to 28.4% in those with colorectal cancer. The causes of the obstruction may be benign postoperative adhesions, a focal malignant or benign deposit, or relapse or diffuse carcinomatosis. The symptoms, which are almost always present, are intestinal colic, continuous abdominal pain, nausea, and vomiting. Although surgery should be the primary treatment for malignant obstruction, it is now recognized that some patients with advanced disease or in generally poor condition are unfit for surgery and require alternative management to relieve distressing symptoms. A number of treatment options are now available for the patient with advanced cancer who develops intestinal obstruction. In this review, the indications for surgery are examined, the use of nasogastric tube and percutaneous gastrostomy evaluated, and the pharmacologic approach described.

AB - Bowel obstruction is a common and distressing outcome in patients with abdominal or pelvic cancer. Patients may develop bowel obstruction at any time in their clinical history, with a prevalence ranging from 5.5% to 42% in those with ovarian cancer and from 10% to 28.4% in those with colorectal cancer. The causes of the obstruction may be benign postoperative adhesions, a focal malignant or benign deposit, or relapse or diffuse carcinomatosis. The symptoms, which are almost always present, are intestinal colic, continuous abdominal pain, nausea, and vomiting. Although surgery should be the primary treatment for malignant obstruction, it is now recognized that some patients with advanced disease or in generally poor condition are unfit for surgery and require alternative management to relieve distressing symptoms. A number of treatment options are now available for the patient with advanced cancer who develops intestinal obstruction. In this review, the indications for surgery are examined, the use of nasogastric tube and percutaneous gastrostomy evaluated, and the pharmacologic approach described.

UR - http://www.scopus.com/inward/record.url?scp=0028356350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028356350&partnerID=8YFLogxK

M3 - Article

C2 - 7528546

AN - SCOPUS:0028356350

VL - 6

SP - 351

EP - 357

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 4

ER -